Slide 1: Adjusted Diluted Earnings Per Share
Adjusted Diluted Earnings Per Share* $2.59 Increased «. 4.4% “Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company's market leadership in the midst of macroeconomic challenges. lam continually energized by the focus and passion of my Johnson &
Slide 2: Cautionary Note on Forward-looking Statements
Cautionary Note on Forward-looking Statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strate
Slide 3: Strategic Partnerships, Collaborations & Licensing Arrangements
Strategic Partnerships, Collaborations & Licensing Arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships:
Slide 4: 2nd Quarter 2022 Earnings Call
nd 2 Quarter 2022 Earnings Call July 19, 2022 Joaquin Duato Chief Executive Officer
Slide 5: Slide 5
Slide 6: Slide 6
Slide 7: Slide 7
Slide 8: Slide 8
Slide 9: New Consumer Health Company Designate Leadership Team
New Consumer Health Company Designate Leadership Team Luani Alvarado Carlton Lawson Jan Meurer Meri Stevens Chief People Officer Group President, Chief Growth Officer Chief Operations Officer People Experience, Diversity, Equity Europe, Middle East and Global Franchise Organizations, End-to-end Qual
Slide 10: Slide 10
Slide 11: Slide 11
Slide 12: Agenda
Agenda 1 CEO Remarks 2 Sales Performance and Earnings Review 3 Capital Allocation and Guidance 4 Q&A Joaquin Duato Joseph J. Wolk Jessica Moore Chief Executive Officer Executive Vice President Vice President Chief Financial Officer Investor Relations 12
Slide 13: 2nd Quarter 2022 Sales
2nd Quarter 2022 Sales % CHANGE Dollars in Billions Regional Sales Results Q2 2022 Q2 2021 Reported Operational1 U.S. $12.2 $11.9 2.3% 2.3% Europe 6.1 5.7 7.3 20.7 Western Hemisphere 1.5 1.4 12.4 14.9 (ex U.S.) Asia-Pacific, Africa 4.2 4.4 (3.6) 4.7 International 11.8 11.4 3.8 13.9 Worldwide (WW) $2
Slide 14: 2nd Quarter 2022 Financial Highlights
2nd Quarter 2022 Financial Highlights Dollars in Billions, except EPS Reported %; Operational %1 Sales GAAP Earnings GAAP EPS $24.0 $6.3 $2.35 $23.3 $4.8 $1.80 Q2 2022 Q2 2021 Q2 2022 Q2 2021 Q2 2022 Q2 2021 3.0%; 8.0%1 (23.3)% (23.4)% Adjusted Earnings2 Adjusted EPS2 $6.9 $2.59 $6.6 $2.48 Q2 2022 Q
Slide 15: Consumer Health Highlights – 2nd Quarter 2022
Consumer Health Highlights – 2nd Quarter 2022 Solid adjusted operational growth2 driven by OUS OTC Reported3: WW (1.3)%, U.S. (3.6)%, Int’l 0.6% Key Drivers of Operational Performance1,3 Operational1,3: WW 2.3%, U.S. (3.6)%, Int’l 7.3% • Growth driven by strong OUS Cough/Cold/Flu season and strong p
Slide 16: Pharmaceutical Highlights – 2nd Quarter 2022
Pharmaceutical Highlights – 2nd Quarter 2022 Continued above-market performance primarily driven by Oncology and Immunology Reported3: WW 6.7%, U.S. 4.2%, Int’l 9.8% Key Drivers of Operational Performance1,3 • Growth driven by continued strong uptake of STELARA in Crohn’s Disease and Operational1,3:
Slide 17: MedTech Highlights – 2nd Quarter 2022
MedTech Highlights – 2nd Quarter 2022 Operational growth1 reflects continued commercial execution & innovation partially offset by impacts related to COVID-19 Reported: WW (1.1)%, U.S. 1.6%, Int’l (3.6)% Key Drivers of Operational Performance1 Operational1: WW 3.4%, U.S. 1.6%, Int’l 5.1% Interventio
Slide 18: Condensed Consolidated Statement of Earnings
Condensed Consolidated Statement of Earnings 2nd Quarter 2022 2022 2021 % (Unaudited; Dollar and Shares in Millions Except Per Share Figures) Increase Amount % to Sales Amount % to Sales (Decrease) Sales to customers $24,020 100.0 $23,312 100.0 3.0 Cost of products sold 7,919 33.0 7,587 32.5 4.4 Gro
Slide 19: Adjusted Income Before Tax by Segment
Adjusted Income Before Tax by Segment1 2nd Quarter 2022 % to Sales $8.2B 2Q 2022 2Q 2021 $7.8B Pharmaceutical3 42.0% 39.4% MedTech 26.5% 28.6% $5.6 $4.9 Consumer Health3 25.9% 28.6% Total 34.0% 33.4% Pharmaceutical $1.8 $2.0 MedTech $1.0 $1.1 Consumer Health ($0.2) ($0.2) 2 Expenses Not Allocated to
Slide 20: Joseph J. Wolk
Joseph J. Wolk Executive Vice President, Chief Financial Officer
Slide 21: Notable Announcements in 2nd Quarter 2022
1 Notable Announcements in 2nd Quarter 2022 Pharmaceutical • Regulatory Decisions: – European Commission Grants Conditional Approval of CARVYKTI (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma – Janssen Announces
Slide 22: Capital Allocation Strategy
Capital Allocation Strategy Dollars in Billions Q2 2022 Cash and Marketable Capital Allocation $33 Securities HIGHER PRIORITY Debt ($33) Organic growth business needs Net Debt $0 Free cash flow1 Free Cash Flow1,2 ~$8 Note: values may have been rounded Q2 2022: Competitive dividends Investment in M&A
Slide 23: 2022 P&L Guidance
2022 P&L Guidance Company maintains midpoints of Adjusted Operational Sales and Adjusted Operational EPS July April Comments Adjusted Operational Sales1,2,6 6.5% - 7.5% 6.5% - 7.5% Maintain $97.3B - $98.3B $97.3B - $98.3B Operational Sales2,6 6.5% - 7.5% 6.5% - 7.5% Maintain $93.3B - $94.3B $94.8B -
Slide 24: Euro Falls to Equal the U.S. Dollar for the First Time in 20 Years
Euro Falls to Equal the U.S. Dollar for the First Time in 20 Years Source: The New York Times; FactSet As of July 13, 2022, 8:42AM EST 24
Slide 25: 2022 Sales Considerations
2022 Sales Considerations July April Adjusted Operational Sales1,2,4 6.5% - 7.5% 6.5% - 7.5% $97.3B - $98.3B $97.3B - $98.3B Operational Sales2,4 6.5% - 7.5% 6.5% - 7.5% $93.3B - $94.3B $94.8B - $95.8B Estimated Reported Sales3,4 2.1% - 3.1% 3.8% - 4.8% Phasing Considerations by Segment Consumer Hea
Slide 26: Q&A
Q&A Joaquin Duato Joseph J. Wolk Jessica Moore Chief Executive Officer Executive Vice President, Vice President, Chief Financial Officer Investor Relations
Slide 27: Goluenatohweon
Goluenatohweon